Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Maryland: - The University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in Maryland: - University of Maryland Medical Center (UMMC) — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Maryland: - American Oncology Partners of Maryland, PA — Bethesda, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Maryland: - Center for Cancer and Blood Disorders ( Site 5439) — Bethesda, Maryland
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in Maryland: - GC2202 Study Site 111 — Bethesda, Maryland
Phase 3 Recruiting Industry
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who h…
Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT07342478
Sites in Maryland: - The Center for Cancer and Blood Disorders-Bethesda — Bethesda, Maryland
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Maryland: - Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Maryland: - Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Maryland: - American Oncology Partners of Maryland Pa — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Maryland: - Johns Hopkins / Sydney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Maryland: - University of Maryland Medical Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Maryland: - Sidney Kimmel Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Maryland: - The Center for Cancer and Blood Disorders (CCBD) — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in…
Sponsor: Lin BioScience, Inc
NCT ID: NCT05756322
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement (recurrent) or that…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06965114
Sites in Maryland: - NCI - Center for Cancer Research — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of th…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03383575
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficu…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06364423
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML)…
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04050280
Sites in Maryland: - University of Maryland Greenebaumn Comprehensive Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05442515
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Maryland: - Johns Hopkins School of Medicine — Baltimore, Maryland
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Maryland: - John Hopkins Cancer Center — Baltimore, Maryland